Author Archive | Geeta Sandhu

Background: Semi-mechanistic PKPD models [1] have been previously used to describe the time-course of granulopoiesis and resulting neutropenia from cytotoxic cancer chemotherapy. The B cycle of Hyper-CVAD comprises of intravenously administered high-dose methotrexate (MTX) followed by short sequential infusions of cytarabine for treatment of aggressive non-Hodgkin lymphoma (NHL) for up to four cycles [2]. Neutropenia […]

Background: Cytotoxic anticancer drugs methotrexate and cytarabine are incorporated into various high-dose multi-agent chemotherapy regimens (e.g. hyper-CVAD) for aggressive non-Hodgkin lymphoma (NHL). Methotrexate and cytarabine have narrow therapeutic windows and display large inter-patient variability on pharmacokinetic (PK) parameters thus creating difficulty in standardising doses within a population. Studies have shown that neutropenic events after chemotherapy […]